Latest "Plexxikon Inc." News Stories

03:55 EST 27th February 2020 | BioPortfolio

Here are the most relevant search results for "Plexxikon Inc." found in our extensive news archives from over 250 global news sources.

More Information about Plexxikon Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Plexxikon Inc. for you to read. Along with our medical data and news we also list Plexxikon Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Plexxikon Inc. Companies for you to search.

Showing "Plexxikon" News Articles, all 9

Saturday 1st February 2020

Global Anaplastic Thyroid Cancer Drug Market Data Survey Report 20152025 [Published by HeyReport] Prices from USD $1275

SummaryThe global Anaplastic Thyroid Cancer Drug market will reach xxx Million USD in 2020 with CAGR xx% 20202025. The main contents of the report including:Global market size and forecastRegional market size, production data and export importKey manufacturers profile, products services, sales data of businessGlobal market size by Major EndUseGlobal market size by Major TypeKey manufacturers are...

Monday 27th January 2020

Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint

Trial met primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2 positive metastatic gastric cancer Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced positive topline results from the pivotal phase 2 DESTINY-Gastric01 trial of DS-8201, a HER2 directed antibody drug conjugate (...

Friday 13th December 2019

Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma

             Basel, 13 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentriq® (atezolizumab) to Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) helped to reduce t...

Wednesday 11th December 2019

DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer Trial

Daiichi Sankyo and AstraZeneca’s DS-8201 demonstrated an impressive 14.8 month median duration of response and 16.4 month median progression-free survival   Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today presented positive detailed data from the global pivotal phase 2 single-arm DESTINY-Breast01 trial of DS-8201 ([fam-] trastuzumab deruxtecan), an invest...

Tuesday 19th November 2019

Positive Pivotal Data for Daiichi Sankyo’s DS-8201 ([Fam]-Trastuzumab Deruxtecan) in Patients with HER2 Positive Metastatic Breast Cancer to be Presented at SABCS

Objective response rate, progression-free survival, duration of response and safety data from DS-8201 pivotal study in HER2 positive metastatic breast cancer (DESTINY-Breast01) to be unveiled Trial-in-progress updates from phase 3 development program of DS-8201 in HER2 positive and HER2 low metastatic breast cancer, along with phase 1/2 trial of U3-1402 in HER3 expressing metastatic breast can...

Wednesday 6th November 2019

Daiichi Sankyo Data at ASH Showcases Scientific and Clinical Advancements Across AML/Blood Cancer Portfolio

Three oral presentations to feature analyses from global pivotal phase 3 QuANTUM-R study of quizartinib Updated phase 1 study results for valemetostat in patients with relapsed/refractory non-Hodgkin lymphomas, including ATL/L Abstracts demonstrate advancements in science and progress in clinical development of novel targeted therapies for patients with AML and other blood cancers   Dai...

Thursday 31st October 2019

Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute

First-in-human phase 1/2 study evaluating DS-7300, a B7-H3 targeting ADC, in patients with advanced/unresectable or metastatic solid tumors B7-H3 is a protein overexpressed in various types of cancers DS-7300 is the fourth ADC to enter the clinic utilizing Daiichi Sankyo’s proprietary DXd technology and the first being jointly developed in a strategic partnership with Sarah Cannon Research...

Thursday 17th October 2019

[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) date for [fam-] trastuzumab deruxtecan, an investigational HER2 targeting an...

Tuesday 24th September 2019

Escient Pharmaceuticals Announces Appointment of K. Peter Hirth to Board of Directors

--Co-founder, former CEO of Plexxikon brings proven track record building platform-based companies and delivering novel medicines for patients-- Escient Pharmaceuticals, Inc., a biotechnology company advancing first-in-class G Protein Coupled Receptor (GPCR)-targeted drugs to address unmet needs for a broad range of therapeutic indications, today announced the appointment of K. Peter Hirth to it...

Quick Search

News Quicklinks